Current Assets

AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value

Moderna AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value increased by 800.0% to $9.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 350.0%, from $2.00M to $9.00M. Over 4 years (FY 2021 to FY 2025), AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value shows a downward trend with a -62.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.

Analysis

StatementBalance Sheet Statement
SectionCurrent Assets
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ4 2019
Last reportedQ1 2026May 1, 2026

How to read this metric

A high value may indicate short-term market volatility affecting the portfolio, while a low value suggests portfolio stability.

Detailed definition

The fair value of debt securities classified as available-for-sale or trading that are currently in an unrealized loss p...

Peer comparison

Commonly used in financial services to assess the duration and severity of investment portfolio impairments.

Metric ID: afs_debt_securities_unrealized_loss_less_12m_fv

Historical Data

18 periods
 Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$52.00M$271.00M$357.00M$373.00M$241.00M$59.00M$46.00M$14.00M$4.00M$11.00M$9.00M$1.00M$6.00M$2.00M$2.00M$0.00$1.00M$9.00M
QoQ Change+421.2%+31.7%+4.5%-35.4%-75.5%-22.0%-69.6%-71.4%+175.0%-18.2%-88.9%+500.0%-66.7%+0.0%-100.0%+800.0%
YoY Change+363.5%-78.2%-87.1%-96.2%-98.3%-81.4%-80.4%-92.9%+50.0%-81.8%-77.8%-100.0%-83.3%+350.0%
Range$0.00$373.00M
CAGR-33.8%
Avg YoY Growth-13.9%
Median YoY Growth-81.6%

AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value at Other Companies

Frequently Asked Questions

What is Moderna's afs and trading securities - unrealized loss position (<12 months) fair value?
Moderna (MRNA) reported afs and trading securities - unrealized loss position (<12 months) fair value of $9.00M in Q1 2026.
How has Moderna's afs and trading securities - unrealized loss position (<12 months) fair value changed year-over-year?
Moderna's afs and trading securities - unrealized loss position (<12 months) fair value increased by 350.0% year-over-year, from $2.00M to $9.00M.
What is the long-term trend for Moderna's afs and trading securities - unrealized loss position (<12 months) fair value?
Over 4 years (2021 to 2025), Moderna's afs and trading securities - unrealized loss position (<12 months) fair value has grown at a -62.8% compound annual growth rate (CAGR), from $52.00M to $1.00M.
What does afs and trading securities - unrealized loss position (<12 months) fair value mean?
The current market value of debt investments that have been worth less than their cost for less than a year.